Glenmark Pharmaceuticals Limited (GLENMARK) AI Stock Analysis

• Market Cap: ₹601.29B
• Dividend Yield: 0.12%
• Average Volume (3M): 18.91K
• Price to Earnings (P/E): 79.8
• Beta (1Y): 0.79
• Revenue Growth: 10.99%
• EPS Growth: N/A
• Country: IN
• Employees: 14,989
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.66
• Shares Outstanding: 282,200,800
• 10 Day Avg. Volume: 22,219
• 30 Day Avg. Volume: 18,909
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹2,155.00
• Price Target Upside: 1.14% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 54 Neutral
• Price Target: ₹2,045.00 ▼(-4.02% Downside)

Glenmark Pharmaceuticals' overall stock score is primarily influenced by its strong revenue growth and stable operational efficiency. However, significant challenges such as profitability volatility, high leverage, and liquidity concerns weigh heavily on the score. The technical analysis presents a mixed picture with slightly positive short-term trends but bearish momentum indicators. The high P/E ratio suggests overvaluation, further impacting the overall score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates Glenmark's ability to expand its market presence and product portfolio, enhancing long-term business sustainability.

Research and Development

Robust R&D supports Glenmark's competitive edge in developing new products, crucial for maintaining leadership in the pharmaceutical industry.

Market Presence

A broad market presence allows Glenmark to leverage diverse revenue streams and mitigate risks associated with market-specific downturns.

Negative Factors

Profitability Volatility

Volatile profitability can undermine investor confidence and affect Glenmark's ability to reinvest in growth initiatives, impacting long-term stability.

High Leverage

High leverage increases financial risk and limits flexibility, potentially constraining Glenmark's ability to invest in future growth opportunities.

Negative Cash Flow

Negative cash flow indicates potential liquidity challenges, which could hinder Glenmark's operational capabilities and investment in strategic initiatives.

Glenmark Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

Glenmark Pharmaceuticals Limited is a global pharmaceutical company headquartered in Mumbai, India. It operates in the healthcare sector, focusing on the research, development, manufacture, and marketing of branded and generic formulations. Glenmark is involved in the therapeutic areas of dermatology, oncology, respiratory, and cardiovascular diseases. The company is known for its robust pipeline of new chemical entities and biosimilars, and it has a significant presence in both emerging and developed markets.

How the Company Makes Money

Glenmark Pharmaceuticals Limited generates revenue through the sale of its pharmaceutical products across various therapeutic areas. The company's key revenue streams include the sale of branded generics, specialty and over-the-counter (OTC) products, and active pharmaceutical ingredients (APIs). Glenmark's earnings are bolstered by its strong research and development capabilities, which enable it to introduce innovative drugs and expand its product portfolio. Additionally, strategic partnerships and collaborations with other pharmaceutical companies and research organizations play a crucial role in enhancing its market reach and driving revenue growth.

Glenmark Pharmaceuticals Limited Financial Statement Overview

Summary

Glenmark Pharmaceuticals shows strong revenue growth and stable operational efficiency, but faces challenges with profitability volatility and high leverage. Liquidity concerns are evident due to negative cash flow from operations, indicating a need for improved cash management.

Income Statement

Glenmark Pharmaceuticals has shown robust revenue growth over the years, with a significant increase in Total Revenue from the previous periods. However, the Net Profit Margin is volatile, impacted by inconsistent net income figures. The EBIT and EBITDA margins are stable, indicating efficient core operations despite the net income fluctuations. Overall, there is strong revenue growth with profitability challenges.

Balance Sheet

The company's debt levels are relatively high compared to its equity, as reflected in the Debt-to-Equity ratio, which poses a risk if not managed carefully. However, the Return on Equity (ROE) is moderate, and the Equity Ratio suggests a reasonable proportion of assets financed by equity. The balance sheet shows a need for improved leverage management.

Cash Flow

Glenmark's cash flow from operations is negative in recent years, highlighting potential liquidity issues. The Free Cash Flow is also negative, indicating that the company is not generating enough cash to cover its capital expenditures. The Operating Cash Flow to Net Income Ratio shows a disconnect between reported earnings and cash generation, necessitating closer management of operational cash flows.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	132.14B	134.35B	118.13B	115.83B	121.74B	108.06B
Gross Profit	79.85B	54.60B	32.59B	36.30B	41.09B	35.80B
EBITDA	20.92B	20.92B	11.34B	11.58B	22.26B	21.79B
Net Income	10.47B	10.47B	-15.02B	2.97B	9.42B	9.70B
Balance Sheet
Total Assets	160.50B	160.50B	143.59B	193.72B	170.83B	156.04B
Cash, Cash Equivalents and Short-Term Investments	17.68B	17.68B	16.64B	11.73B	14.43B	12.14B
Total Debt	24.73B	24.73B	12.31B	46.08B	39.62B	49.86B
Total Liabilities	72.00B	72.00B	65.11B	95.32B	76.45B	85.39B
Stockholders Equity	88.49B	88.49B	78.48B	94.74B	90.87B	70.65B
Cash Flow
Free Cash Flow	0.00	-15.77B	-11.64B	176.29M	3.19B	3.56B
Operating Cash Flow	0.00	-8.28B	-2.65B	6.25B	11.09B	11.31B
Investing Cash Flow	0.00	20.94M	45.44B	-5.28B	-3.33B	-6.75B
Financing Cash Flow	0.00	7.87B	-39.06B	-774.56M	-5.20B	-4.42B

Glenmark Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2130.70
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GLENMARK, the sentiment is Positive. The current price of 2130.7 is above the 20-day moving average (MA) of 1999.33, above the 50-day MA of 2041.70, and above the 200-day MA of 1627.26, indicating a bullish trend. The MACD of 29.60 indicates Negative momentum. The RSI at 66.74 is Neutral, neither overbought nor oversold. The STOCH value of 93.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:GLENMARK.

Glenmark Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	76 Outperform	₹635.75B	18.75		0.37%	7.76%	-2.84%
ALKEM	72 Outperform	₹651.25B	28.51		0.83%	4.49%	11.22%
LUPIN	72 Outperform	₹933.01B	25.20		0.59%	12.40%	63.16%
BIOCON	67 Neutral	₹487.20B	113.91		0.14%	6.80%	-75.66%
GLAXO	66 Neutral	₹470.09B	49.47		1.94%	6.65%	48.47%
GLENMARK	54 Neutral	₹601.29B	79.77		0.12%	10.99%	―
Sector *	51 Neutral	$7.93B	-0.35	-43.30%	2.25%	22.54%	-2.22%

Glenmark Pharmaceuticals Limited Corporate Events

Glenmark Receives FDA Warning for Indore Facility, Ensures No Supply Disruption

Glenmark Pharmaceuticals Limited has received a warning letter from the U.S. FDA concerning its facility in Indore, Madhya Pradesh, following an inspection conducted in February 2025. The company has stated that this warning will not disrupt supplies or affect current revenues from the facility’s operations. Glenmark is committed to addressing the FDA’s concerns promptly and maintaining compliance with CGMP quality standards, emphasizing that no data integrity issues were observed.